Credit Agricole S A Sells 70,213 Shares of DaVita Inc. $DVA

Key Points

• Credit Agricole S A sold 70,213 shares of DaVita Inc., reducing its holdings by 55.7% to approximately 55,885 shares valued at $8.55 million.
• DaVita reported earnings of $2.95 per share, exceeding analyst estimates by $0.25, with quarterly revenue increasing by 6.1% year-over-year to $3.38 billion.
• Wall Street analysts have diverse opinions on DaVita, with a consensus rating of "Hold" and target price revisions varying from $148 to $160.

Credit Agricole S A lessened its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 55.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,885 shares of the company's stock after selling 70,213 shares during the quarter. Credit Agricole S A owned approximately 0.07% of DaVita worth $8,549,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. UMB Bank n.a. grew its position in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. National Pension Service grew its position in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after acquiring an additional 84 shares during the last quarter. Copia Wealth Management bought a new position in DaVita in the 4th quarter valued at $30,000. Y.D. More Investments Ltd purchased a new stake in shares of DaVita in the 1st quarter worth $35,000. Finally, Coppell Advisory Solutions LLC lifted its holdings in shares of DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after buying an additional 100 shares during the period. Institutional investors own 90.12% of the company's stock.

DaVita Trading Up 0.1%

Shares of NYSE DVA opened at $137.58 on Friday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The stock has a market capitalization of $9.84 billion, a P/E ratio of 13.53, a price-to-earnings-growth ratio of 0.98 and a beta of 1.09. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The business has a fifty day moving average price of $139.55 and a 200 day moving average price of $144.38.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The firm had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm's quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial set a $148.00 target price on DaVita in a report on Friday, August 8th. Finally, Barclays lowered their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.